arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NEKTAR THERAPEUTICS

NKTR
$76.47 ▲ +2.95 (+4.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NEKTAR THERAPEUTICS faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth -43.9%
Op. Margin -253.7%
ROIC -155.8%
FCF / Share $-12.37
Trailing P/E
Price / Book 17.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$55.23M
↓ -43.9%
Net Income Profit after all expenses
$-164.08M
↓ -37.9%
Operating Margin Operating profit as % of sales
-253.7%
↓ -137.3% 0th
FCF / Share Free cash flow per share
$-12.37
↓ -1335.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
3
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters